Quitting Smoking with COPD: What Changes

For a smoker with COPD, quitting is the single most effective thing in the evidence. Not one of the most effective: the most. The Lung Health Study, which followed 5,887 people with mild to moderate COPD over five years, found that sustained quitters had significantly slower rates of lung function decline compared to continuing smokers [1]. Eleven-year follow-up confirmed the finding [3]. Fourteen-and-a-half-year follow-up showed lower all-cause mortality in the smoking intervention group [2]. No COPD medication, not inhalers, not steroids, not supplemental oxygen, has shown a comparable effect on the rate of decline.

What quitting does for COPD

COPD involves progressive, largely irreversible narrowing of the airways and destruction of lung tissue. The primary driver of this progression in smokers is ongoing exposure to combustion products. Quitting removes that driver.

The Lung Health Study quantified the difference. Sustained quitters lost FEV1 (forced expiratory volume, the standard measure of lung function) at approximately 31 mL per year, close to the normal age-related decline. Continuing smokers lost approximately 62 mL per year [1]. That difference, roughly halving the rate of decline, accumulates over years into a substantial preservation of lung function.

To put these numbers in context: the threshold for noticeable breathlessness during daily activities typically falls around an FEV1 of 50-60% of predicted normal. For oxygen dependence, it is roughly 30% of predicted. A smoker whose FEV1 is declining at 62 mL per year will cross each of these thresholds years earlier than one declining at 31 mL per year. The difference between the two trajectories, compounded over 10 or 15 years, can be the difference between walking to the grocery store independently and needing supplemental oxygen to cross a room.

This is not recovery. Quitting does not restore lung tissue that has already been destroyed. Emphysema involves the permanent destruction of alveoli, the tiny air sacs where gas exchange occurs, and that structural damage is irreversible. What quitting does is change the trajectory: from a steep decline toward disability and oxygen dependence to a gentler slope that keeps function above the threshold of daily impairment for longer. The earlier in the disease course someone quits, the more function is preserved.

The Lung Health Study in detail

The Lung Health Study is the single most important trial in COPD cessation research, and its findings warrant a closer look. The study enrolled 5,887 smokers aged 35-60 with mild to moderate airflow obstruction (FEV1 55-90% of predicted). Participants were randomized to either a smoking intervention program (behavioral counseling plus nicotine gum) or usual care [1].

At 5 years, sustained quitters in the intervention group showed a small initial improvement in FEV1 during the first year after quitting (approximately 47 mL, likely reflecting reduced airway inflammation and mucus) followed by a gradual decline at approximately 31 mL per year. Continuing smokers declined at approximately 62 mL per year throughout. Intermittent quitters, those who quit and relapsed one or more times, fell between the two groups, their rate of decline tracking with how much of the follow-up period they spent abstinent.

The Lung Health Study II extended follow-up to 11 years and confirmed that the benefit of cessation on FEV1 decline was sustained, not a temporary effect that diminished over time [3]. The sustained quitters maintained their trajectory advantage over the full follow-up period. The 14.5-year mortality analysis showed that participants in the smoking intervention group had lower all-cause mortality, lower cardiovascular mortality, and lower lung cancer mortality than those in the usual care group [2].

These findings established that cessation in COPD is not merely beneficial but is the dominant intervention for the disease. Nothing else in COPD management comes close to the effect size of quitting on the rate of lung function decline.

What the guidelines recommend

The GOLD guidelines, the international standard for COPD management, list smoking cessation as the primary recommendation at every stage of the disease [5]. Before adding a new inhaler, before adjusting bronchodilator dosing, before pulmonary rehabilitation: is the patient still smoking, and have they been offered cessation support?

This prioritization is not rhetorical. The GOLD guidelines stratify COPD management by severity (GOLD stages 1-4) and symptoms (groups A-E). At every combination of severity and symptom burden, cessation is listed as the first intervention. Pharmacological COPD management (bronchodilators, inhaled corticosteroids, PDE4 inhibitors) manages symptoms and reduces exacerbation frequency but does not change the underlying rate of disease progression the way cessation does.

A Cochrane review specific to COPD populations found evidence supporting both NRT and varenicline [6]. A dedicated trial of varenicline in 504 people with mild to moderate COPD found significantly higher quit rates compared to placebo [4]. The evidence does not suggest that COPD patients respond differently to cessation pharmacotherapy than the general smoking population; if anything, the motivation to quit is often higher because the consequences of continued smoking are already visible in daily symptoms.

Which quit method for COPD

Method	Evidence in COPD	Quit rate advantage	Considerations
Combination NRT (patch + gum/lozenge)	Supported by Cochrane review	~15-25% at 6 months	Available OTC; no prescription barrier
Varenicline	Dedicated COPD trial	~25-30% at 6 months	Requires prescription; strongest single method
Bupropion	Limited COPD-specific evidence; effective in general population	~15-20% at 6 months	May be considered if varenicline unavailable
Single NRT (patch alone)	Supported; less effective than combination	~15-20% at 6 months	Better than no pharmacotherapy
Behavioral support alone	Modest effect	~5-10% at 6 months	Best combined with pharmacotherapy

NRT is safe in COPD. The nicotine itself does not cause the lung damage associated with smoking; the harm comes from the thousands of combustion products in cigarette smoke. Carbon monoxide, tar, acrolein, hydrogen cyanide, and particulate matter are the agents of injury, not nicotine. This is worth stating explicitly because some smokers with COPD are told, or assume, that they cannot use NRT because of their lung condition. The patch delivers nicotine through the skin, and gum delivers it through the oral mucosa; neither involves any inhalation of combustion products.

The choice between NRT and varenicline in COPD is pragmatic. Varenicline has the highest single-agent efficacy and a dedicated COPD trial [4]. It requires a prescription, which means a clinician visit. Combination NRT is available over the counter and has Cochrane evidence in this population. For a patient who can access a prescriber, varenicline is the strongest single option. For one who cannot, combination NRT is an effective and immediately available alternative.

The conversation with the clinician

For smokers with COPD, the cessation conversation is not a general wellness recommendation. It is a disease management intervention with a stronger evidence base than most COPD treatments. The clinician conversation should include method selection (NRT, varenicline, or both), behavioral support options, and a realistic discussion of what to expect during withdrawal.

Some smokers with COPD report that they feel worse in the first few days after quitting: more coughing, more mucus production. This is the airways beginning to recover mucociliary clearance, which smoking suppresses. The cilia, tiny hair-like structures that line the airways and sweep mucus and debris upward, are paralyzed by chronic smoke exposure. Within days of cessation, they begin functioning again, and the accumulated mucus starts to clear. It is uncomfortable, temporary, and a sign of healing. Knowing this in advance helps prevent it from being interpreted as a reason to resume smoking.

The anxiety about increased coughing is particularly acute in COPD patients who already cough daily. The distinction is that the post-cessation cough is productive (clearing accumulated material) and resolves within weeks to months, while the COPD cough from continued smoking is chronic and progressive. Clinicians can prepare patients for this transition and reassure them that it is expected and time-limited.

Exacerbation risk after quitting

COPD exacerbations, acute worsening of symptoms that often require hospitalization, are a major driver of disease progression and mortality. Continued smoking increases exacerbation frequency. Cessation reduces it, though the timeline for this benefit is less precisely quantified than the FEV1 data.

The mechanism is straightforward. Smoking causes chronic airway inflammation and impairs the immune defenses that protect against respiratory infections, which are the most common trigger for exacerbations. Quitting allows airway inflammation to decrease and immune function to improve. The result is fewer infections, fewer exacerbations, and fewer hospitalizations over time.

For patients who have been hospitalized for a COPD exacerbation, the post-discharge period is a particularly important window for cessation intervention. The combination of a recent health scare and a brief period of forced abstinence (during hospitalization) creates both motivation and a head start on withdrawal. Initiating cessation pharmacotherapy before discharge, rather than waiting for a follow-up visit, improves the odds of sustained abstinence.

What this means if you’re deciding

If you have COPD and you smoke, the evidence for quitting is as strong as medical evidence gets. The method matters less than the quitting: any supported method is better than unsupported, and the highest-efficacy methods (combination NRT, varenicline) give the best odds. But the critical thing is the cessation itself. Every year of continued smoking accelerates a decline that quitting would slow.

The numbers from the Lung Health Study are worth repeating: 31 mL per year for sustained quitters versus 62 mL per year for continuing smokers. Over 10 years, that is a difference of roughly 310 mL of preserved FEV1, which in practical terms can be the difference between climbing stairs independently and being unable to walk to the bathroom without stopping to breathe.

The prescription conversation for varenicline is worth having. If that is not accessible, combination NRT is available without a prescription and has Cochrane evidence in COPD populations [6]. Neither requires a lung specialist; a primary care physician can prescribe varenicline, and a pharmacist can advise on NRT.

Open questions

Whether e-cigarettes are a viable cessation tool for people with COPD who cannot quit by other means is an active area of research. The evidence is currently insufficient to recommend them in this population, and the long-term effects of inhaling e-cigarette aerosol on already-compromised airways are unknown. The guideline position is that proven cessation methods should be used first.

Whether starting cessation pharmacotherapy at the time of COPD diagnosis (when airflow obstruction is confirmed by spirometry) improves long-term outcomes compared to the usual approach of offering cessation at any clinical encounter is a question with intuitive appeal but limited direct evidence. The Lung Health Study enrolled patients with mild to moderate COPD, and the benefit was clear; whether a targeted “cessation at diagnosis” protocol would improve uptake and outcomes is worth studying.

A doctor or pharmacist can help choose the right approach for your health history. The Quitline (1-800-QUIT-NOW) provides free coaching and can sometimes supply NRT.